HYGEIA HEALTH

6078
10.7200.19% ( +0.020 )
Delay Closed: Nov 16, 16:08:11

Overview

HYGEIA HEALTH (6078)

Hygeia Healthcare Holdings Co., Limited offers oncology healthcare services in the People's Republic of China. The company owns and operates private for-profit...

Open
10.700
High
10.860
Low
10.660
Prev. Close
10.700
Volume
905.80K
Turnover
9.74M
Avg Price
10.752
Bid/Ask Ratio
-73.33%
Amplitude
1.87%
52wk High
14.550
Volume Ratio
0.42
Turnover Ratio
0.15%
52wk Low
8.100
HK Mkt Cap
6.45B
Market CapHKD
6.45B
P/ETTM
32.04
P/EDynamic
10.88
P/EStatic
--
EPSTTM
0.335
EPSDynamic
0.985
EPSStatic
--
BVPS
13.28
P/B
0.81
HK Shares
601.82M
Dividend YieldTTM
--
DividendTTM
--
Shares
601.82M
Min lot size
200
Currency
HKD

HYGEIA HEALTH Analyst Rating

View more

Forecast & Rating

Oct 27, 2026
Price forecast
HK$16.3452.41%
Forecast & RatingBuy
15analysts
  • Strong buy60.00%
  • Buy13.33%
  • Hold26.67%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    HYGEIA HEALTH (6078.HK) closed nearly flat today, gaining just 0.19% to 10.72 HKD after the stock briefly rallied to an intraday high of 10.86 HKD during morning trading before retreating in the afternoon session. The muted performance reflects cautious investor sentiment despite a backdrop of solid recent earnings—Q1 and Q2 2026 both posted 10%+ year-over-year EPS growth and maintained a stable 13.1% net profit margin—as the company's revenue growth of merely 3-4% and return on equity of 7.4% fall short of expectations that might drive meaningful price recovery. Positioned 26% below its 52-week high of 14.55 HKD and having declined 15.5% year-to-date, the stock trades above its 20- and 60-day moving averages. Though most brokers maintain buy ratings with consensus targets above current prices, recent commentary has questioned whether the company's ongoing share buyback initiative can effectively address the underlying structural weakness in hospital business growth.

  2. Nov, 13

    Hygeia Healthcare declined 0.37% to HK$10.7 today, mainly as profit-taking pressure following a 12.09% surge the previous day. Intraday trading showed a swing from HK$10.54 in the morning session to HK$10.82 in the afternoon, spanning a 2.6% range. Recent fundamentals remain steady: Q2 revenue of HK$1.133B grew 3.89% year-over-year, net profit expanded 9.82% YoY, and EPS climbed 10.62% YoY; Q1 EPS similarly rose 11.3% YoY, reflecting earnings stability. Management has stepped up share buyback programs, and most brokers maintain buy ratings. From a valuation perspective, the stock has retreated 15.68% year-to-date and trades 26.46% below its 52-week high of HK$14.55, yet a forward PE of 31.98 paired with an ROE of around 7.4% may temper mid-term growth potential.

  3. Nov, 12

    Hygeia Health closed at HKD 10.74, down 0.55% from the previous close of HKD 10.80, marking profit-taking after a recent weekly gain of +12.09%. The afternoon session peaked at HKD 10.86 at 13:02 before fading toward the close, reflecting market consolidation following the prior rally. On the fundamental side, Q2 EPS of HKD 0.2421 grew 10.62% year-over-year, operating revenue of HKD 1.133 billion rose 3.89% year-over-year, and net profit expanded 9.82% year-over-year, sustaining operational growth with a stable net margin of 13.13%. Relative to the 52-week high of HKD 14.55 set in February, the current price is down 26.19%; year-to-date performance stands at -15.37%, though it has recovered 32.59% from the June low of HKD 8.10, suggesting some price support in the lower range. The company continues share buybacks to protect shareholder value. However, a P/E ratio of 32.1x sits at elevated levels, and turnover of 0.18% reflects limited market participation.

  4. Nov, 11

    Hygeia Health closed at HK$10.80, essentially flat with the previous close of HK$10.81, reflecting market consolidation following recent buyback announcements and analyst endorsements. The earnings picture shows steady operational performance: Q2 revenue grew 3.89% year-over-year to HK$1.13 billion, while net profit surged 9.82% to HK$148.7 million; Q1 mirrored this trend with 4.53% revenue growth and 10.5% profit expansion, with EPS growth hovering above 10% in both quarters. On valuation metrics, the stock trades at a relatively elevated PE of 32.28, though the PB ratio of 0.81 suggests conservative pricing relative to book value. Positioning-wise, the stock remains down 14.89% year-to-date and 25.77% below its 52-week high of HK$14.55 reached in early February, though it continues to trade above both the 20-day and 60-day moving averages. While management has actively pursued share buybacks and majority brokers maintain buy ratings, market observers have flagged concerns about whether repurchases can offset the modest organic growth trajectory of the hospital operations.

  5. Nov, 10

    Hygeia Health retreated 0.13% to HK$10.81 today, extending profit-taking following yesterday's sharp 12.09% surge amid widespread 'buy' ratings from brokers. Intraday showed divergence: the stock reached a high of HK$10.99 at 09:32 (up 2.3%), then weakened through the afternoon close. From a valuation stance, the stock has fallen 14.81% year-to-date and trades 25.7% below its 52-week peak of HK$14.55. Recent quarterly earnings reveal EPS growth of 10.62% and 11.3% year-over-year for Q2 and Q1 respectively, while Q2 revenue at HK$1.1325B posted only 3.89% year-over-year growth, suggesting profit expansion is margin-driven rather than revenue-driven. The company continues aggressive share buybacks, yet market concerns about shrinking core hospital operations temper further rebound potential.

News